Ultimately, by targeting the tumor-associated antigen Wilms’ tumor-1 (WT1), the tumor-antigen specificity was assessed by demonstrating a superior antigen-specific T cell stimulating capacity of PD-L-silenced IL-15 DCs. Here, WT1 is linked to neoplasm.